18 August 2015

LSE: VER

Vernalis plc announces that Ms Lisa Amster Schoenberg, aged 48, has been appointed to the Board as a Non-Executive Director with effect from 1 September 2015.

Ms Schoenberg has extensive marketing experience of pharmaceutical products in both primary and secondary care in the US. For the past two years, she has acted as pharmaceutical marketing consultant to a number of organisations. From 1993 until 2013 Ms Schoenberg worked for AstraZeneca Pharmaceuticals (US) in a number of senior marketing positions, culminating as VP Sales & Marketing, Growth Brands USA. After graduating from the University of Michigan in 1988, Ms Schoenberg joined Amster & Co as Financial Analyst. She then undertook an MBA at Wharton School, University of Pennsylvania, specialising in Healthcare Management and Marketing, before joining AstraMerck in 1993.

Peter Fellner, Chairman of Vernalis plc, commented:

"I am delighted to welcome Lisa to the Vernalis Board. Her experience in launching and commercialising products in the US market in both primary care and speciality medicines and her knowledge of the changing US marketing environment and how it is likely to evolve will be invaluable for the Board. We look forward to her contribution, as we continue to build value for Vernalis' shareholders."

Disclosures:
Ms Schoenberg is a trustee of the Shipley School and currently on the board of directors of the Jewish Family & Children Services Philadelphia.
There is no other information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Ms Schoenberg's appointment with effect from 1 September 2015 as a Non-Executive Director of the Company.

-- ends --

Enquiries:

Vernalis plc:

 

Ian Garland, Chief Executive Officer

+44 (0) 118 938 0015

David Mackney, Chief Financial Officer

 

Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8000

Dr Julian Feneley

 

Laura White

 

Henry Fitzgerald-O'Connor

 

Shore Capital (Joint Broker)

+44 (0)20 7408 4090

Bidhi Bhoma

 

Toby Gibbs

 

FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell

 

Simon Conway

 

Notes to Editors

About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has two approved products; Tuzistra™ XR targeting the US prescription cough cold market and, frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

For further information about Vernalis, please visit www.vernalis.com.

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch